PolyPid (PYPD) Stock Forecast, Price Target & Predictions
PYPD Stock Forecast
PolyPid stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
PYPD Analyst Ratings
According to 3 Wall Street analysts, PolyPid's rating consensus is 'Buy'. The analyst rating breakdown for PYPD stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 06, 2022 | Raymond James | - | Outperform | Downgrade |
| Sep 02, 2022 | Guggenheim | - | Neutral | Upgrade |
| Aug 11, 2022 | BMO Capital | Outperform | Outperform | Hold |
PolyPid's last stock rating was published by Raymond James on Sep 06, 2022. The company Downgrade its PYPD rating from "null" to "Outperform".
PolyPid Financial Forecast
PolyPid Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
PolyPid's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PYPD's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
PolyPid EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict PYPD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than PolyPid's previous annual EBITDA (undefined) of $NaN.
PolyPid Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-3.32M | $-3.98M | $-4.35M | $-5.17M | $-5.66M | $-5.14M | $-6.53M |
| High Forecast | $-3.32M | $-3.98M | $-4.35M | $-5.17M | $-5.66M | $-5.14M | $-6.53M |
| Low Forecast | $-3.32M | $-3.98M | $-4.35M | $-5.17M | $-5.66M | $-5.14M | $-6.53M |
| Surprise % | - | - | - | - | - | - | - |
PolyPid's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PYPD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
PolyPid SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
PolyPid's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PYPD last annual SG&A of $NaN (undefined).
PolyPid EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.66 | $-0.79 | $-0.87 | $-1.03 | $-1.13 | $-1.02 | $-1.30 |
| High Forecast | $-0.66 | $-0.79 | $-0.87 | $-1.03 | $-1.13 | $-1.02 | $-1.30 |
| Low Forecast | $-0.66 | $-0.79 | $-0.87 | $-1.03 | $-1.13 | $-1.02 | $-1.30 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, PolyPid's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PYPD previous annual EPS of $NaN (undefined).
PolyPid Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.05 | $5.50 | 10900.00% | Buy |
| INAB | IN8bio | $0.32 | $14.00 | 4275.00% | Buy |
| KPRX | Kiora Pharmaceuticals | $3.66 | $120.00 | 3178.69% | Buy |
| BWV | Onconetix | $0.18 | $4.00 | 2122.22% | Buy |
| ELEV | Elevation Oncology | $0.61 | $9.00 | 1375.41% | Buy |
| CUE | Cue Biopharma | $0.59 | $5.00 | 747.46% | Buy |
| PYPD | PolyPid | $3.47 | $25.00 | 620.46% | Buy |
| VACC | Barinthus Biotherapeutics | $5.00 | $22.00 | 340.00% | - |
| INMB | INmune Bio | $5.46 | $22.00 | 302.93% | Buy |
| VRPX | Virpax Pharmaceuticals | $0.83 | $3.00 | 261.45% | - |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| ANIX | Anixa Biosciences | $3.35 | $8.00 | 138.81% | Buy |
| PYXS | Pyxis Oncology | $3.78 | $9.00 | 138.10% | Buy |
| ZURA | Zura Bio | $3.70 | $5.00 | 35.14% | Buy |
PYPD Forecast FAQ
Is PolyPid a good buy?
Yes, according to 3 Wall Street analysts, PolyPid (PYPD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of PYPD's total ratings.
What are PolyPid's analysts' financial forecasts?
PolyPid's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-17.334M (high $-17.334M, low $-17.334M), average SG&A $0 (high $0, low $0), and average EPS is $-3.45 (high $-3.45, low $-3.45). PYPD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-16.828M (high $-16.828M, low $-16.828M), average SG&A $0 (high $0, low $0), and average EPS is $-3.349 (high $-3.349, low $-3.349).